Kelyniam Global, Inc., ("KLYG") Announces Private Investment to Public Entity ("PIPE") Closure of Securities Offering
Kelyniam Global (OTC: KLYG), a custom cranial implants manufacturer, has completed a private placement of restricted common stock to accredited investors, closing on November 30, 2024. The offering did not include warrants. The company plans to utilize the proceeds to support its 2025 growth objectives, focusing on:
- Enhanced sales and marketing for current and pipeline products
- Regulatory and FDA filing fees for new product launches
- Geographical expansion across US neurology-focused trauma centers
CEO Ross Bjella noted strong performance in the first three quarters and expressed confidence in deploying funds to build scale across distribution channels and geographies in 2025 and beyond.
Kelyniam Global (OTC: KLYG), un produttore di impianti cranici su misura, ha completato un collocamento privato di azioni comuni restrittive per investitori accreditati, chiudendo il 30 novembre 2024. L'offerta non ha incluso warrant. L'azienda prevede di utilizzare i proventi per sostenere i propri obiettivi di crescita del 2025, concentrandosi su:
- Aumento delle vendite e del marketing per i prodotti attuali e in fase di sviluppo
- Spese per la registrazione e le richieste alla FDA per i nuovi lanci di prodotto
- Espansione geografica nei centri traumatologici focalizzati sulla neurologia negli Stati Uniti
Il CEO Ross Bjella ha osservato una performance solida nei primi tre quarti e ha espresso fiducia nell'uso dei fondi per costruire scala attraverso i canali di distribuzione e le aree geografiche nel 2025 e oltre.
Kelyniam Global (OTC: KLYG), un fabricante de implantes craneales personalizados, ha completado una colocación privada de acciones comunes restringidas para inversores acreditados, cerrando el 30 de noviembre de 2024. La oferta no incluyó garantías. La empresa planea utilizar los ingresos para apoyar sus objetivos de crecimiento para 2025, enfocándose en:
- Mejorar ventas y marketing para productos actuales y en desarrollo
- Costos de regulación y presentación ante la FDA para nuevos lanzamientos de productos
- Expansión geográfica en los centros de trauma enfocados en neurología en EE. UU.
El CEO Ross Bjella mencionó un fuerte desempeño en los primeros tres trimestres y expresó confianza en desplegar fondos para construir escala a través de canales de distribución y geografías en 2025 y más allá.
Kelyniam Global (OTC: KLYG), 맞춤형 두개골 임플란트 제조업체가 인증된 투자자들을 대상으로 제한된 보통주를 사모하는 공모를 완료하였으며, 2024년 11월 30일에 종료되었습니다. 이 제안은 워런트를 포함하지 않았습니다. 회사는 2025년 성장 목표를 지원하기 위해 조달한 자금을 사용할 계획이며, 다음에 중점을 둘 것입니다:
- 현재 및 개발 중인 제품의 판매 및 마케팅 강화
- 신제품 출시를 위한 규제 및 FDA 제출 수수료
- 미국 신경학 중심의 외상 센터에 대한 지리적 확장
CEO 로스 비젤라(Ross Bjella)는 첫 세 분기 동안 강력한 성과를 언급하며 2025년 및 그 이후의 유통 채널과 지역에 걸친 규모 확장을 위해 자금을 배치할 수 있다는 자신감을 표명했습니다.
Kelyniam Global (OTC: KLYG), un fabricant d'implants crâniens sur mesure, a complété un placement privé d'actions ordinaires restreintes pour des investisseurs accrédités, clôturant le 30 novembre 2024. L'offre n'incluait pas de bons de souscription. L'entreprise prévoit d'utiliser les produits pour soutenir ses objectifs de croissance pour 2025, en se concentrant sur :
- Amélioration des ventes et du marketing pour les produits actuels et en développement
- Frais réglementaires et frais de dépôt auprès de la FDA pour les nouveaux lancements de produits
- Expansion géographique dans les centres de trauma axés sur la neurologie aux États-Unis
Le PDG Ross Bjella a noté une performance solide au cours des trois premiers trimestres et a exprimé sa confiance dans le déploiement des fonds pour construire une échelle à travers les canaux de distribution et les régions géographiques en 2025 et au-delà.
Kelyniam Global (OTC: KLYG), ein Hersteller von individuellen Schädelimplantaten, hat eine private Platzierung von eingeschränkten Stammaktien für akkreditierte Investoren abgeschlossen, die am 30. November 2024 abgeschlossen wurde. Das Angebot beinhaltete keine Optionen. Das Unternehmen plant, die Erlöse zu nutzen, um seine Wachstumsziele für 2025 zu unterstützen, mit einem Fokus auf:
- Erweiterte Verkaufs- und Marketingmaßnahmen für bestehende und zukünftige Produkte
- Regulatorische Gebühren und FDA-Anmeldungen für neue Produkteinführungen
- Geografische Expansion in neurologische Traumazentren in den USA
CEO Ross Bjella bemerkte eine starke Leistung in den ersten drei Quartalen und äußerte Vertrauen, dass die Mittel eingesetzt werden, um die Skalierung über Vertriebskanäle und geografische Regionen im Jahr 2025 und darüber hinaus voranzutreiben.
- Successful completion of private placement funding
- Strong performance reported for first three quarters of 2024
- Strategic expansion plans across multiple growth channels
- No warrant dilution in the offering structure
- Share dilution from new stock issuance
Proceeds to Further Growth Objectives in 2025
The company intends to use the proceeds to accelerate its 2025 growth objectives across several investments. Chief among these objectives include additional sales and marketing efforts for current and pipeline products, regulatory and FDA filing fees for new product introductions and additional geographical expansion to territories and trauma centers across
"I am pleased that our shareholders continue to express confidence in the strategic direction of Kelyniam. The first three quarters of the year have been stellar for business", said Ross Bjella, CEO of the Company. "We intend to thoughtfully deploy these funds in building scale across all of our distribution channels and geographies in 2025 and beyond."
Kelyniam Inc., specializes in the rapid production of custom prosthetics utilizing computer aided design and computer aided manufacturing of advanced medical grade polymers. The Company develops, manufactures, and distributes custom cranial and craniofacial implants for patients. Kelyniam works directly with surgeons, health systems and payors to improve clinical and cost-of-care outcomes. Kelyniam's web site address is www.Kelyniam.com.
As a cautionary note to investors, certain matters discussed in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; the Company's ability to execute its service and product sales plans; and changes in the status of ability to market products.
View original content:https://www.prnewswire.com/news-releases/kelyniam-global-inc-klyg-announces-private-investment-to-public-entity-pipe-closure-of-securities-offering-302331846.html
SOURCE Kelyniam Global Inc
FAQ
What is the purpose of KLYG's 2024 private placement offering?
When did Kelyniam Global (KLYG) close its private placement offering?
How will KLYG use the proceeds from its 2024 private placement?
Were warrants included in KLYG's 2024 private placement offering?
How has KLYG's business performance been in 2024?
